CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Lanthanum carbonate hydrate

Last Updated: June 28, 2007
Result type: Reports
Project Number: S0100
Product Line: Common Drug Review

Generic Name: Lanthanum carbonate hydrate

Brand Name: Fosrenol

Manufacturer: Shire BioChem Inc.

Indications: Hyperphosphatemia, end-stage renal disease

Submission Type: New

Project Status: Complete

Date Recommendation Issued: January 30, 2008

Recommendation Type: Do not list